{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T18:27:37Z","timestamp":1776882457526,"version":"3.51.2"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004169","name":"Meiji Seika Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004169","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ejphar.2023.176202","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T03:29:55Z","timestamp":1700623795000},"page":"176202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["ME3183, a novel phosphodiesterase-4 inhibitor, exhibits potent anti-inflammatory effects and is well tolerated in a non-clinical study"],"prefix":"10.1016","volume":"962","author":[{"given":"Natsuki","family":"Kubota-Ishida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chizuko","family":"Kaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8599-5868","authenticated-orcid":false,"given":"Shogo","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsubasa","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Matsuhira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iori","family":"Okura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3544-7008","authenticated-orcid":false,"given":"Naoki","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Isshiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ko","family":"Kumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Tabata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejphar.2023.176202_bib1","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jdermsci.2014.10.005","article-title":"Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP","volume":"76","author":"Andoh","year":"2014","journal-title":"J. Dermatol. Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2023.176202_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/187152807780077318","article-title":"Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis","volume":"6","author":"Baumer","year":"2007","journal-title":"Inflamm. Allergy - Drug Targets"},{"issue":"12","key":"10.1016\/j.ejphar.2023.176202_bib3","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.str.2004.10.004","article-title":"Structural basis for the activity of drugs that inhibit phosphodiesterases","volume":"12","author":"Card","year":"2004","journal-title":"Structure"},{"key":"10.1016\/j.ejphar.2023.176202_bib4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/1744666X.2017.1304820","article-title":"2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis","volume":"13","author":"Cheape","year":"2017","journal-title":"Expet Rev. Clin. Immunol."},{"key":"10.1016\/j.ejphar.2023.176202_bib5","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1124\/jpet.103.064691","volume":"310","author":"Claveau","year":"2004","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2023.176202_bib6","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1365-2133.2008.08941.x","article-title":"Itch characteristics in atopic dermatitis: results of a web-based questionnaire","volume":"160","author":"Dawn","year":"2009","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.ejphar.2023.176202_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1124\/mol.61.1.20","article-title":"Molecular docking of competitive phosphodiesterase inhibitors","volume":"61","author":"Dym","year":"2002","journal-title":"Mol. Pharmacol."},{"issue":"19","key":"10.1016\/j.ejphar.2023.176202_bib8","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1016\/j.febslet.2012.07.058","article-title":"Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center","volume":"586","author":"Freund","year":"2012","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejphar.2023.176202_bib9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/978-3-642-17969-3_7","article-title":"Small molecule allosteric modulators of phosphodiesterase 4","volume":"204","author":"Gurney","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"issue":"16","key":"10.1016\/j.ejphar.2023.176202_bib10","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","article-title":"Apremilast for Beh\u00e7et\u2019s syndrome\u2014a phase 2, placebo-controlled study","volume":"372","author":"Hatemi","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.ejphar.2023.176202_bib11","article-title":"BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis","volume":"20","author":"Herrmann","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejphar.2023.176202_bib12","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/s41598-023-28987-1","article-title":"Epithelial cell-derived cytokine TSLP activates regulatory T cells by enhancing fatty acid uptake","volume":"13","author":"Kasuya","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2023.176202_bib13","first-page":"P1340","article-title":"Safety, tolerability, and pharmacokinetics of ME3183, a novel oral PDE4 inhibitor in healthy adult volunteers","volume":"2021","author":"Kato","year":"2021","journal-title":"EADV"},{"key":"10.1016\/j.ejphar.2023.176202_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174258","article-title":"Anti-inflammatory effects of a novel phosphodiesterase-4 inhibitor, AA6216, in mouse dermatitis models","volume":"906","author":"Kubota-Ishida","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176202_bib15","first-page":"164","article-title":"Pruritus: an overview. What drives people to scratch an itch?","volume":"85","author":"Lavery","year":"2016","journal-title":"Ulster Med. J."},{"key":"10.1016\/j.ejphar.2023.176202_bib16","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176202_bib17","doi-asserted-by":"crossref","first-page":"41512","DOI":"10.1074\/jbc.M312568200","article-title":"Protein kinase A inhibits leukotriene synthesis by phosphorylation of 5-lipoxygenase on serine 523","volume":"279","author":"Luo","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2023.176202_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173508","article-title":"A novel phosphodiesterase 4 inhibitor, AA6216, reduces macrophage activity and fibrosis in the lung","volume":"885","author":"Matsuhira","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176202_bib19","first-page":"21","article-title":"Phosphodiesterase-4 inhibition in psoriasis","volume":"11","author":"Milakovic","year":"2021","journal-title":"Psoriasis (Auckl)"},{"issue":"6","key":"10.1016\/j.ejphar.2023.176202_bib20","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jid.2017.12.029","article-title":"The genetics of chronic itch: gene expression in the skin of patients with atopic dermatitis and psoriasis with severe itch","volume":"138","author":"Nattkemper","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejphar.2023.176202_bib21","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.tips.2004.01.003","article-title":"Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4)","volume":"25","author":"O'Donnell","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.ejphar.2023.176202_bib22","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1124\/pharmrev.120.000273","article-title":"The molecular biology of phosphodiesterase 4 enzymes as pharmacological targets: an interplay of isoforms, conformational states, and inhibitors","volume":"73","author":"Paes","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejphar.2023.176202_bib23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (efficacy and safety trial evaluating the effects of apremilast in psoriasis [esteem] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejphar.2023.176202_bib24","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s40265-017-0746-9","article-title":"Chronic pruritus: current and emerging treatment options","volume":"77","author":"Pereira","year":"2017","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.ejphar.2023.176202_bib25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00403-007-0745-x","article-title":"Study of substance P and its receptor neurokinin-1 in psoriasis and their relation to chronic stress and pruritus","volume":"299","author":"Remr\u00f6d","year":"2007","journal-title":"Arch. Dermatol. Res."},{"issue":"23","key":"10.1016\/j.ejphar.2023.176202_bib26","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa2201737","article-title":"Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis","volume":"386","author":"Richeldi","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ejphar.2023.176202_bib27","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI0215506","article-title":"Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis","volume":"110","author":"Robichaud","year":"2002","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.ejphar.2023.176202_bib28","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1172\/JCI124606","article-title":"Epithelial cell\u2013derived cytokines: more than just signaling the alarm","volume":"129","author":"Roan","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.ejphar.2023.176202_bib29","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"4","author":"Sbidian","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"issue":"9","key":"10.1016\/j.ejphar.2023.176202_bib30","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.cellsig.2014.05.014","article-title":"Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity","volume":"26","author":"Schafer","year":"2014","journal-title":"Cell. Signal."},{"issue":"4","key":"10.1016\/j.ejphar.2023.176202_bib31","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1476-5381.2009.00559.x","article-title":"Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis","volume":"159","author":"Schafer","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176202_bib32","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","article-title":"Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.ejphar.2023.176202_bib33","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jid.2018.10.043","article-title":"A phase 2 randomized trial of apremilast in patients with atopic dermatitis","volume":"139","author":"Simpson","year":"2019","journal-title":"J. Invest. Dermatol."},{"issue":"3\u20134","key":"10.1016\/j.ejphar.2023.176202_bib34","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0898-6568(96)00173-8","article-title":"Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases","volume":"9","author":"Souness","year":"1997","journal-title":"Cell. Signal."},{"issue":"10","key":"10.1016\/j.ejphar.2023.176202_bib35","first-page":"1224","article-title":"Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study","volume":"11","author":"Souza","year":"2012","journal-title":"J. Drugs Dermatol. JDD"},{"key":"10.1016\/j.ejphar.2023.176202_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12946","article-title":"The TNF\/IL-23\/IL-17 axis\u2014head-to-head trials comparing different biologics in psoriasis treatment","volume":"92","author":"Ten Bergen","year":"2020","journal-title":"Scand. J. Immunol."},{"issue":"2","key":"10.1016\/j.ejphar.2023.176202_bib37","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1164\/ajrccm.157.2.9708012","article-title":"Phosphodiesterase isozymes: molecular targets for novel antiasthma agents","volume":"157","author":"Torphy","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.ejphar.2023.176202_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13555-013-0023-0","article-title":"Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases","volume":"3","author":"Wittmann","year":"2013","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.ejphar.2023.176202_bib39","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1046\/j.1365-2133.2000.03829.x","article-title":"The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis","volume":"143","author":"Yosipovitch","year":"2000","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejphar.2023.176202_bib40","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1046\/j.1365-4362.2002.01460.x","article-title":"Itch characteristics in Chinese patients with atopic dermatitis using a new questionnaire for the assessment of pruritus","volume":"41","author":"Yosipovitch","year":"2002","journal-title":"Int. J. Dermatol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923007161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923007161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:21:18Z","timestamp":1757978478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299923007161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":40,"alternative-id":["S0014299923007161"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.176202","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ME3183, a novel phosphodiesterase-4 inhibitor, exhibits potent anti-inflammatory effects and is well tolerated in a non-clinical study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.176202","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Meiji Seika Pharma Co., Ltd. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"176202"}}